TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause

A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

NCT05265286 ·Status: COMPLETED ·Phase: PHASE2

Canadian Hemophilia Prophylaxis Study

NCT01085344 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A

NCT01125813 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection

NCT05251090 ·Status: COMPLETED ·Phase: PHASE1

Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

NCT06142552 ·Status: RECRUITING ·Phase: PHASE3

Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.

NCT04060836 ·Status: UNKNOWN ·Phase: PHASE1

Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A

NCT00717626 ·Status: COMPLETED ·Phase: PHASE2

Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants

NCT03876301 ·Status: COMPLETED

Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A

NCT02930317 ·Status: UNKNOWN ·Phase: PHASE3

Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A

NCT01619046 ·Status: UNKNOWN ·Phase: PHASE3

Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A

NCT00989196 ·Status: COMPLETED ·Phase: PHASE2

Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A

NCT02461992 ·Status: COMPLETED ·Phase: PHASE1

2-cohort Study of Adult Patients With Severe Hemophilia A in Greece

NCT02319070 ·Status: COMPLETED

PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A

NCT02492984 ·Status: COMPLETED ·Phase: PHASE4

Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.

NCT04061109 ·Status: UNKNOWN ·Phase: PHASE3

Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A

NCT01790828 ·Status: COMPLETED

Data Registry in Chinese Hemophilia A and B Patients

NCT07101224 ·Status: COMPLETED

Ex Vivo Laboratory Assays Application for Therapy Tailoring in Patients With Severe Bleeding Disorders

NCT02324517 ·Status: UNKNOWN

Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."

NCT02581969 ·Status: COMPLETED

Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China

NCT03598725 ·Status: UNKNOWN ·Phase: PHASE4

Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age

NCT00759655 ·Status: TERMINATED ·Phase: PHASE3

Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors

NCT00221195 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Study Evaluating The Safety Of Xyntha In Usual Care Settings

NCT00765726 ·Status: TERMINATED ·Phase: PHASE4

Hemophilia and Bone Metabolism: Study of Monocytic Populations and Inflammatory Proteins

NCT04206033 ·Status: COMPLETED

Quality of Life Study of Helixate NexGen

NCT01053715 ·Status: COMPLETED